Psychopharmacology

, Volume 217, Issue 2, pp 211–219 | Cite as

Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development

  • Regina C. Casper
  • Allyson A. Gilles
  • Barry E. Fleisher
  • Joan Baran
  • Gregory Enns
  • Laura C. Lazzeroni
Original Investigation

Abstract

Objectives

This study evaluated the question whether length of in utero exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants might affect neonatal outcome and psychomotor development in infancy.

Methods

Birth outcome was determined in the offspring of 55 women with major depressive disorder who used SSRI medication for different durations during their pregnancies. At an average age of 14 months, children underwent a pediatric examination and an evaluation with the Bayley Scales of Infant Development (BSID-II).

Results

Duration of in utero exposure to SSRIs was negatively associated with total Apgar scores, specifically the activity subscale. Odds ratios for a low score (<2) on this scale were 3.8 and 6.0 at 1 and 5 min, respectively. Newborns with longer exposure were more often admitted to the Neonatal Intensive Care Unit (p < .03). Mental Development Index scores of the infants were not associated with the length of gestational exposure to SSRIs. A longer duration of exposure increased the risk for lower Psychomotor Developmental Index and Behavioral Rating Scale scores in infancy (p = 0.012 and p = 0.007, respectively) on the BSID-II.

Conclusions

The findings provide evidence that the length of prenatal SSRI antidepressant use can affect neonatal adjustment and can have an effect on psychomotor test scores in infancy. Importantly, the children’s mental development and motor function by neurological examination were within the normal range. Timing of exposure to SSRIs during susceptible periods of fetal development and variations in the severity of maternal depression may have contributed to the associations.

Keywords

SSRI antidepressants Duration of fetal exposure Apgar scores Mental and psychomotor development 

References

  1. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM (2007) Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356:2684–2692PubMedCrossRefGoogle Scholar
  2. Ansorge M, Zhou M, Lira A, Hen R, Gingrich J (2004) Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306(5697):879–881PubMedCrossRefGoogle Scholar
  3. Bakker MK, Kolling P, van den Berg PB, de Walle HE, de Jong van den Berg LT (2008) Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. Br J Clin Pharmacol 65:600–606PubMedCrossRefGoogle Scholar
  4. Bayley N (1993) Bayley scales of infant development, 2nd edn. The Psychological Corporation, San AntonioGoogle Scholar
  5. Beck A (1972) Depression: causes and treatment. University of Pennsylvania Press, PhiladelphiaGoogle Scholar
  6. Beck A, Ward C, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571PubMedGoogle Scholar
  7. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D (2007) First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 80:18–27PubMedCrossRefGoogle Scholar
  8. Casper R, Fleisher B, Lee-Ancajas J, Gilles A, Gaylor E, DeBattista A, Hoyme H (2003) Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 142:402–408PubMedCrossRefGoogle Scholar
  9. Chambers C, Johnson K, Dick L, Felix R, Jones K (1996) Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 335:1010–1015PubMedCrossRefGoogle Scholar
  10. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA (2006) Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354:579–587PubMedCrossRefGoogle Scholar
  11. Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di Gianantonio E, Clementi M, Weber-Schoendorfer C, Schaefer C, Ornoy A (2008) Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 66:695–705PubMedGoogle Scholar
  12. DiPietro JA, Novak MF, Costigan KA, Atella LD, Reusing SP (2006) Maternal psychological distress during pregnancy in relation to child development at age two. Child Dev 77:573–587PubMedCrossRefGoogle Scholar
  13. DSM I (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, D.CGoogle Scholar
  14. Ehrenstein V, Pedersen L, Grijota M, Nielsen GL, Rothman KJ, Sorensen HT (2009) Association of Apgar score at five minutes with long-term neurologic disability and cognitive function in a prevalence study of Danish conscripts. BMC Pregnancy Childbirth 9:14PubMedCrossRefGoogle Scholar
  15. First M, Spitzer RL, Gibbon M, Williams JBW (1997) Structured clinical interview for DSM IV axis I disorders. APA, Washington, D.CGoogle Scholar
  16. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62PubMedCrossRefGoogle Scholar
  17. Hansen H, Mikkelsen J (1998) Long term effects on serotonin transporter mRNA expression of chronic neonatal exposure to a serotonin reuptake inhibitor. Eur J Pharmacol 352:307–315PubMedCrossRefGoogle Scholar
  18. Hendrick V, Stowe Z, Altshuler L, Hwang S, Lee E, Haynes D (2003) Placental passage of antidepressant medications. Am J Psychiatry 160:993–996PubMedCrossRefGoogle Scholar
  19. Homberg JR, Schubert D, Gaspar P (2009) New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol Sci 31:60–65PubMedCrossRefGoogle Scholar
  20. Jacobs B, Azmitia E (1992) Structure and function of the brain serotonin system. Physiol Rev 72:165–215PubMedGoogle Scholar
  21. Jacobs B, Fornal C (1995) Serotonin and behavior, a general hypothesis. In: Bloom F, Kupfer D (eds) Psychopharmacology, the fourth generation of progress. Raven, New York, pp 461–469Google Scholar
  22. Laine K, Heikkinen T, Ekblad U, Kero P (2003) Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 60:720–726PubMedCrossRefGoogle Scholar
  23. Loubinoux I, Pariente J, Boulanouar K, Carel C, Manelfe C, Rascol O, Celsis P, Chollet F (2002) A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects. Neuroimage 15:26–36PubMedCrossRefGoogle Scholar
  24. Loughhead AM, Fisher AD, Newport DJ, Ritchie JC, Owens MJ, DeVane CL, Stowe ZN (2006) Antidepressants in amniotic fluid: another route of fetal exposure. Am J Psychiatry 163:145–147PubMedCrossRefGoogle Scholar
  25. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA (2007) First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356:2675–2683PubMedCrossRefGoogle Scholar
  26. Lund N, Pedersen LH, Henriksen TB (2009) Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 163:949–954PubMedCrossRefGoogle Scholar
  27. Mattson SN, Calarco K, Kao KK, Jones KL, Chambers CD (2004) Neurodevelopmental outcome of infants and toddlers exposed prenatally to selective serotonin reuptake inhibitors. Clinical and Molecular Teratology 70:261Google Scholar
  28. Merlob P, Birk E, Sirota L, Linder N, Berant M, Stahl B, Klinger G (2009) Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol 85:837–841PubMedCrossRefGoogle Scholar
  29. Misri S, Reebye P, Kendrick K, Carter D, Ryan D, Grunau RE, Oberlander TF (2006) Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am J Psychiatry 163:1026–1032PubMedCrossRefGoogle Scholar
  30. Mortensen JT, Olsen J, Larsen H, Bendsen J, Obel C, Sorensen HT (2003) Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and anti-epileptics. Eur J Epidemiol 18:769–771PubMedCrossRefGoogle Scholar
  31. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL (2005) Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 293:2372–2383PubMedCrossRefGoogle Scholar
  32. Nulman I, Rovet J, Stewart D, Wolpin J, Gardner H, Theis J, Kulin N, Koren G (1997) Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336:258–262PubMedCrossRefGoogle Scholar
  33. Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, Koren G (2002) Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 159:1889–1895PubMedCrossRefGoogle Scholar
  34. Oberlander T, Eckstein Grunau R, Fitzgerald C, Ellwood A, Misri S, Rurak D, Riggs K (2002) Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res 51:443–453PubMedCrossRefGoogle Scholar
  35. Oberlander T, Grunau RE, Fitzgerald C, Papsdorf M, Rurak D, Riggs W (2005) Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 115:411–425PubMedCrossRefGoogle Scholar
  36. Oberlander TF, Reebye P, Misri S, Papsdorf M, Kim J, Grunau RE (2007) Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med 161:22–29PubMedCrossRefGoogle Scholar
  37. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C (2008) Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry 192:338–343PubMedCrossRefGoogle Scholar
  38. Pastuszak A, Schick-Boschetto B, Zuber C (1993) Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). J Am Med Assoc 269:2246–2248CrossRefGoogle Scholar
  39. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH (2009) Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. Bmj 339:b3569PubMedCrossRefGoogle Scholar
  40. Pedersen LH, Henriksen TB, Olsen J (2010) Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 125:e600–e608PubMedCrossRefGoogle Scholar
  41. Radloff L (1977) The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Meas 1:385–401CrossRefGoogle Scholar
  42. Simon G, Cunningham M, Davis R (2002) Outcomes following prenatal antidepressant exposure. Am J Psychiatry 159:2055–2061PubMedCrossRefGoogle Scholar
  43. Stowe Z, Hostetter A, Owens M, Ritchie J, Sternberg K, Cohen L, Nemeroff C (2003) The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations. J Clin Psychiatry 64:73–80PubMedCrossRefGoogle Scholar
  44. Suri R, Altshuler L, Hellemann G, Burt VK, Aquino A, Mintz J (2007) Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 164:1206–1213PubMedCrossRefGoogle Scholar
  45. Thompson B, Wasserman J, Matula K (1996) The factor structure of the behavior rating scale of the Bayley scales of infant development—II: cross-sample, cross-sectional, and cross-method investigations of construct validity. Educ Psychol Meas 56:460–474CrossRefGoogle Scholar
  46. Toh S, Mitchell AA, Louik C, Werler MM, Chambers CD, Hernandez-Diaz S (2009) Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J Clin Psychopharmacol 29:555–560PubMedCrossRefGoogle Scholar
  47. Wisner KL, Sit DK, Hanusa BH, Moses-Kolko EL, Bogen DL, Hunker DF, Perel JM, Jones-Ivy S, Bodnar LM, Singer LT (2009) Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 166:557–566PubMedCrossRefGoogle Scholar
  48. Wogelius P, Norgaard M, Gislum M, Pedersen L, Munk E, Mortensen PB, Lipworth L, Sorensen HT (2006) Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 17:701–704PubMedCrossRefGoogle Scholar
  49. Zeskind PS, Stephens LE (2004) Maternal selective serotonin reuptake inhibitors use during pregnancy and newborn neurobehavior. Pediatrics 113:368–375PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Regina C. Casper
    • 1
  • Allyson A. Gilles
    • 1
  • Barry E. Fleisher
    • 2
  • Joan Baran
    • 2
  • Gregory Enns
    • 3
  • Laura C. Lazzeroni
    • 1
    • 4
  1. 1.Department of Psychiatry and Behavioral SciencesStanford University School of MedicineStanfordUSA
  2. 2.Division of Neonatology and Developmental Medicine, Department of PediatricsStanford University School of MedicineStanfordUSA
  3. 3.Division of Medical Genetics, Department of PediatricsStanford University School of MedicineStanfordUSA
  4. 4.Department of PediatricsStanford University School of MedicineStanfordUSA

Personalised recommendations